Pfizer Strikes $2.6 Billion Deal for Experimental Autoimmune Therapies

By Connor Hart

 

Pfizer entered into a licensing agreement with Starna Therapeutics, obtaining exclusive rights outside Greater China to develop, manufacture and commercialize three early-stage, experimental treatments for autoimmune diseases.

Under the agreement, Starna will receive an upfront payment of $330 million and be eligible to receive up to $2.3 billion in additional payments tied to development and commercial milestones, Pfizer said Wednesday.

Starna would additionally receive royalties on net sales of any approved products.

Pfizer said the agreement will broaden its inflammation and immunology pipeline. The company will lead clinical development of the programs outside Greater China and plans to manufacture finished drug products for initial clinical trials at its U.S. facilities.

Pfizer will have sole and exclusive rights to commercialize all products outside Greater China, while holding an option to expand its territorial rights to include the region, it added.

"In vivo CAR-T is an emerging and promising approach for treating autoimmune diseases, and the patients who might benefit most are those for whom today's options fall short," said Michael Vincent, Pfizer's chief inflammation and immunology officer.

"Pfizer has significant experience in developing and manufacturing RNA-based medicines globally, and Starna's in vivo CAR-T programs and technology give us a powerful way to pursue these approaches," he added.

 

Write to Connor Hart at connor.hart@wsj.com

 

(END) Dow Jones Newswires

November 18, 2026 07:35 ET (12:35 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.

Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.

Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.

Popular

Sponsor Center